FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:304-310 August 1, 1996 Number 5 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white populations. We determined the distribution of PSA and age-specific reference ranges in black men both with and without prostate cancer.

Methods From January 1991 through May 1995, we measured serum PSA in 3475 men with no clinical evidence of prostate cancer (1802 white and 1673 black) and 1783 men with prostate cancer (1372 white and 411 black). We studied the data as a function of age and race to determine the usefulness of measuring PSA in diagnosing prostate cancer.

Results Serum PSA concentrations in black men (geometric mean in controls, 1.48 ng per milliliter; in patients, 7.46) were significantly higher than those in white men (geometric mean in controls, 1.33 ng per milliliter; in patients, 6.28). The values in the controls correlated directly with age. The area under the receiver-operating-characteristic curve was 0.91 for blacks and 0.94 for whites. If traditional age-specific reference ranges were used in screening black men, with the test specificity kept at 95 percent, 41 percent of cases of prostate cancer would be missed. For the test to have 95 percent sensitivity among black men, the following normal reference ranges should be used: for men in their 40s, 0 to 2.0 ng of PSA per milliliter (test specificity, 93 percent); for men in their 50s, 0 to 4.0 ng per milliliter (specificity, 88 percent); for men in their 60s, 0 to 4.5 ng per milliliter (specificity, 81 percent); and for men in their 70s, 0 to 5.5 ng per milliliter (specificity, 78 percent).

Conclusions Serum PSA concentrations can be used to discriminate between men with prostate cancer and those without it among both blacks and whites. Over 40 percent of cases of prostate cancer in black men would not be detected by tests using traditional age-specific reference ranges, which maintain specificity at 95 percent. In this high-risk population, the alternative approach — maintaining sensitivity at 95 percent — may be used with acceptable decrements in specificity.

Source Information

From the Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, D.C. (T.O.M., D.G.M., J.W.M.); the Sections of Clinical Epidemiology (S.J.J.) and Biostatistics (D.J.J.), Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minn.; and the Department of Surgery and Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Md. (W.F.M., D.G.M., J.W.M.). The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the U.S. Army or the Department of Defense.

Address reprint requests to Dr. Moul at the Department of Surgery, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814-4799.

Full Text of this Article

Related Letters:

Prostate-Specific Antigen in Black Men
Jacobson M. W., Sawyer R., Berman J. J., Moore G. W., Swee D. E., Catalona W. J., Moul J. W., Morgan T. O., Jacobson S. J., Oesterling J. E.
Extract | Full Text  
N Engl J Med 1997; 336:133-136, Jan 9, 1997. Correspondence

This article has been cited by other articles:

• Brawley, O. W., Ankerst, D. P., Thompson, I. M. (2009). Screening for Prostate Cancer. CA Cancer J Clin 59: 264-273 [Abstract] [Full Text]  
• Shim, H. B., Lee, S. E., Park, H. K., Ku, J. H. (2007). Histological Diagnosis of Prostate Cancer in Korean Men Aged 70 79 Years. Jpn J Clin Oncol 0: hym093v1-6 [Abstract] [Full Text]  
• Werny, D. M., Thompson, T., Saraiya, M., Freedman, D., Kottiri, B. J., German, R. R., Wener, M. (2007). Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004. Cancer Epidemiol. Biomarkers Prev. 16: 70-76 [Abstract] [Full Text]  
• Werny, D. M., Saraiya, M., Gregg, E. W. (2006). Prostate-specific Antigen Values in Diabetic and Nondiabetic US Men, 2001-2002. Am J Epidemiol 164: 978-983 [Abstract] [Full Text]  
• Saraiya, M., Kottiri, B. J., Leadbetter, S., Blackman, D., Thompson, T., McKenna, M. T., Stallings, F. L. (2005). Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002. Cancer Epidemiol. Biomarkers Prev. 14: 2178-2182 [Abstract] [Full Text]  
• Routh, J. C., Leibovich, B. C. (2005). Adenocarcinoma of the Prostate: Epidemiological Trends, Screening, Diagnosis, and Surgical Management of Localized Disease. Mayo Clin Proc. 80: 899-907 [Abstract]  
• Kelloff, G. J., Coffey, D. S., Chabner, B. A., Dicker, A. P., Guyton, K. Z., Nisen, P. D., Soule, H. R., D'Amico, A. V. (2004). Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer. Clin. Cancer Res. 10: 3927-3933 [Full Text]  
• Carter, H. B. (2004). Prostate Cancers in Men with Low PSA Levels -- Must We Find Them?. NEJM 350: 2292-2294 [Full Text]  
• Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., Kuntz, K. M. (2003). Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen. NEJM 349: 335-342 [Abstract] [Full Text]  
• Cramer, S. D., Chang, B.-L., Rao, A., Hawkins, G. A., Zheng, S. L., Wade, W. N., Cooke, R. T., Thomas, L. N., Bleecker, E. R., Catalona, W. J., Sterling, D. A., Meyers, D. A., Ohar, J., Xu, J. (2003). Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels. JNCI J Natl Cancer Inst 95: 1044-1053 [Abstract] [Full Text]  
• Bhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., Cunningham, G. R. (2003). Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan. J Androl 24: 299-311 [Full Text]  
• Balk, S. P., Ko, Y.-J., Bubley, G. J. (2003). Biology of Prostate-Specific Antigen. JCO 21: 383-391 [Abstract] [Full Text]  
• Jain, S, Bhojwani, A G, Mellon, J K (2002). Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad. Med. J. 78: 646-650 [Abstract] [Full Text]  
• Taylor, J. M. G., Cooper, K. L., Wei, J. T., Sarma, A. V., Raghunathan, T. E., Heeringa, S. G. (2002). Use of Multiple Imputation to Correct for Nonresponse Bias in a Survey of Urologic Symptoms among African-American Men. Am J Epidemiol 156: 774-782 [Abstract] [Full Text]  
• Bunker, C. H., Patrick, A. L., Konety, B. R., Dhir, R., Brufsky, A. M., Vivas, C. A., Becich, M. J., Trump, D. L., Kuller, L. H. (2002). High Prevalence of Screening-detected Prostate Cancer among Afro-Caribbeans: The Tobago Prostate Cancer Survey. Cancer Epidemiol. Biomarkers Prev. 11: 726-729 [Abstract] [Full Text]  
• Baron, A. T., Lafky, J. M., Suman, V. J., Hillman, D. W., Buenafe, M. C., Boardman, C. H., Podratz, K. C., Perez, E. A., Maihle, N. J. (2001). A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women. Cancer Epidemiol. Biomarkers Prev. 10: 1175-1185 [Abstract] [Full Text]  
• Xue, W.-M., Coetzee, G. A., Ross, R. K., Irvine, R., Kolonel, L., Henderson, B. E., Ingles, S. A. (2001). Genetic Determinants of Serum Prostate-specific Antigen levels in Healthy Men from a Multiethnic Cohort. Cancer Epidemiol. Biomarkers Prev. 10: 575-579 [Abstract] [Full Text]  
• Vermeulen, A. (2001). Androgen Replacement Therapy in the Aging Male--A Critical Evaluation. J. Clin. Endocrinol. Metab. 86: 2380-2390 [Full Text]  
• Greiver, M., Rosen, N., for the North York General-Branson Practice-Based, (2000). PSA screening: a view from the front lines. CMAJ 162: 789-790 [Full Text]  
• Bansal, A., Murray, D. K., Wu, J. T., Stephenson, R. A., Middleton, R. G., Meikle, A. W. (2000). Heritability of Prostate-Specific Antigen and Relationship with Zonal Prostate Volumes in Aging Twins. J. Clin. Endocrinol. Metab. 85: 1272-1276 [Abstract] [Full Text]  
• Moul, J. W. (1997). PSA Thresholds for Prostate Cancer Detection. JAMA 278: 699-699 [Abstract]  
• Albertsen, P. C. (1997). Urology. JAMA 277: 1904-1905  
• Catalona, W. J., Smith, D. S., Ornstein, D. K. (1997). Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate Examination: Enhancement of Specificity With Free PSA Measurements. JAMA 277: 1452-1455 [Abstract]  
• Jacobson, M. W., Sawyer, R., Berman, J. J., Moore, G. W., Swee, D. E., Catalona, W. J., Moul, J. W., Morgan, T. O., Jacobson, S. J., Oesterling, J. E. (1997). Prostate-Specific Antigen in Black Men. NEJM 336: 133-136 [Full Text]  
• Jacobsen, S. J., Bergstralh, E. J., Guess, H. A., Katusic, S. K., Klee, G. G., Oesterling, J. E., Lieber, M. M. (1996). Predictive Properties of Serum Prostate-Specific Antigen Testing in a Community-Based Setting. Arch Intern Med 156: 2462-2468 [Abstract]  
• Oesterling, J. E. (1996). Age-Specific Reference Ranges for Serum PSA. NEJM 335: 345-346 [Full Text]